Strategic transaction enables Veracyte to access global markets through a world-class, distributed instrument system, with an initial focus on its pulmonology franchise Provides pathway for long-term revenue growth and margin expansion Veracyte to hold conference call and webcast today at 5:30 p.m.
Findings Presented at 89 th Annual Meeting of the American Thyroid Association SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 2, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced new data that advance understanding of the frequency, positive predictive value and co-occurrence of genomic
Findings derived from Afirma Xpression Atlas analysis of company’s extensive biorepository of thyroid nodule fine needle aspiration samples SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 30, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced today that new data advancing the understanding of
Revenue Grew 32% to $31.0 Million Genomic Test Volume Grew 24% to 9,941 Company Presents Preliminary Data for First-Ever Noninvasive Nasal Swab Test for Lung Cancer Early Detection Conference Call and Webcast Today at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct.
Data presented today at CHEST 2019 Annual Meeting; Company plans to begin making test available in early 2021 Conference call and webcast today at 5:00 p.m. ET to review third quarter 2019 Financial results and the new nasal swab test data SOUTH SAN FRANCISCO --(BUSINESS WIRE)--Oct.
Data Being Presented at CHEST Annual Meeting 2019 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 21, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced data demonstrating the clinical validity of its next-generation Percepta ® Genomic Sequencing Classifier (GSC) and the clinical utility of
Results From Three Studies Presented at CHEST 2019 Suggest Test Increases Physicians’ Confidence in Diagnosis and Can Reduce the Need for Invasive, Risky Procedures SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 21, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced that data from three studies
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 8, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the third quarter 2019 and business progress after the close of market on Tuesday, October 22, 2019 .
Five Studies Reinforcing Clinical Performance and Utility of Company’s Marketed Genomic Tests in Lung Cancer and IPF Diagnosis Will Also Be Presented SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 7, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced that preliminary clinical data for
RNA whole-transcriptome sequencing test informs thyroid cancer treatment decisions at time of diagnosis SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 11, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced the publication of new data demonstrating the clinical and analytical validity of its
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
